Dr. Jhaveri Discusses a Basket Trial of Taselisib in Solid Tumors

Video

In Partnership With:

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Jhaveri says that taselisib is a potent, selective, oral inhibitor of class I PI3Kα, γ, and δ isoforms. In a phase I basket study (NCT01296555), the PI3K inhibitor taselisib was given to patients with PIK3CA-mutated solid tumors who had progressed after, or did not response to, at least 1 prior treatment.

There are 11 cohorts of patients with various solid tumors in the basket trial including endometrial, bladder, head and neck squamous cell carcinoma, cervical, gastric or gastroesophageal junction, small cell lung, triple-negative breast, colorectal, squamous, ovarian, and patients with tumors not otherwise specified. Patients on the study received either 4 mg or 6 mg of taselisib daily. The primary endpoint is safety and tolerability, with a secondary endpoint of antitumor activity.

Related Videos
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD